Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BioTime Establishes Cell Therapy Mnfg. Center in Israel | Contract Pharma

What are you searching for?

Sign in
Breaking News

BioTime Establishes Cell Therapy Mnfg. Center in Israel

To supply OpRegen for ongoing clinical trial for the treatment of dry age-related macular degeneration

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

BioTime, a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, and its majority-owned subsidiary, Cell Cure Neurosciences, have dedicated a new, 800 square-meter, state-of-the-art, cGMP manufacturing center located in the Jerusalem Bio Park on the campus of Hadassah University Hospital in Jerusalem.

The new manufacturing center, initially to be staffed by 25-30 employees, is equipped to produce a range of cell therapies for the treatment of various degenerative human diseases. In the near term, the plan is to supply OpRegen for the company’s ongoing clinical trial program for the treatment of dry age-related macular degeneration, or dry AMD.

“The opening of this new, innovative manufacturing center, demonstrates our continued commitment and is the culmination of a multi-year effort by BioTime and its subsidiary, Cell Cure Neurosciences, to manufacture cell therapies in Israel on an industrial scale,” said Adi Mohanty, co-chief executive officer, BioTime. “Near-term, this new center will manufacture OpRegen doses to treat the patients enrolled in the clinical trial program. Longer term, this center may manufacture additional cell therapies as our products progress into clinical trials and then into commercial distribution.”

Charles Irving, chief executive officer, Cell Cure Neurosciences, said, “The opening of this new manufacturing center is an exciting and important development. Our team in Israel together with BioTime is advancing the OpRegen clinical trial program and the manufacture of OpRegen. We look forward to continued close collaboration with BioTime as it advances additional cell therapy programs in the near future.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics